A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Vaccine Component P3C541b in HIV-1 Seronegative Human Subjects

This study has been completed.

Study NCT00000845 Information provided by National Institute of Allergy and Infectious Diseases (NIAID)

First Received: November 2, 1999 Last Updated: June 23, 2005 History of Changes

No Study Results Posted for this Study

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given